Dr. Patrick Soon-Shiong, Executive Chairman of ImmunityBio, provides an overview of the groundbreaking data related to nogapendekin alfa inbakicept (Anktiva) for non-muscle invasive bladder cancer presented at the AUA 2024 Annual Meeting.

Dr. Soon-Shiong shares how the IL-15 agonist agent works, the next line of research for the immunoagent now that the FDA has approved it for BCG-unresponsive patients with NMIBC, and how ImmunityBio is addressing the worldwide BCG shortage.